China Needs To Balance Equal Access To Affordable Medicines With Sharpening Focus On Innovative Drugs In Mapping Out Future, Say Leaders At DIA Conference
This article was originally published in PharmAsia News
Executive Summary
BEIJING - As China launches sweeping health system reforms in phases over the next decade, the country must balance competing interests in mapping out the future: laying the groundwork for affordable and ultimately universal coverage while promoting the development of research- and capital-intensive innovative medicines, according to drug industry, academic and policy-making leaders who provided glimpses of the road ahead during the second annual meeting of the Drug Information Association in China